Repurposed Epilepsy Medication Shows Potential for Osteoarthritis Treatment

Preclinical research indicates that the FDA-approved epilepsy drug lacosamide may mitigate osteoarthritis by targeting the Nav1.7 protein. This protein, which facilitates pain signaling, also contributes to the degradation of cartilage in joint cells. By inhibiting Nav1.7, the medication appears to suppress pain while simultaneously promoting cartilage repair.

Researchers utilized a specialized hydrogel to deliver the drug directly into the joint. This localized delivery method aims to maintain therapeutic concentrations while minimizing systemic exposure and potential side effects associated with oral administration. The study highlights the drug's ability to stimulate proteins that regulate inflammation and support tissue maintenance.

These findings suggest a potential shift in osteoarthritis management from symptom masking to disease modification. If clinical trials confirm these results, the repurposing of existing sodium channel inhibitors could provide a non-opioid alternative for joint preservation. Further regulatory review and human testing are required to establish safety and efficacy for this specific indication.